

# Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer

K Kaira<sup>\*,1,2</sup>, Y Sunose<sup>3</sup>, K Arakawa<sup>4</sup>, T Ogawa<sup>4</sup>, N Sunaga<sup>1</sup>, K Shimizu<sup>3</sup>, H Tominaga<sup>5</sup>, N Oriuchi<sup>6</sup>, H Itoh<sup>7</sup>, S Nagamori<sup>8</sup>, Y Kanai<sup>8</sup>, A Segawa<sup>2</sup>, M Furuya<sup>2</sup>, M Mori<sup>1</sup>, T Oyama<sup>2</sup> and I Takeyoshi<sup>3</sup>

<sup>1</sup>Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan; <sup>2</sup>Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan; <sup>3</sup>Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan; <sup>4</sup>Department of Surgery, Maebashi Red Cross Hospital, Asahi-cho, Maebashi, Gunma, Japan; <sup>5</sup>Department of Molecular Imaging, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan; <sup>6</sup>Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan; <sup>7</sup>Department of Pathology, Maebashi Red Cross Hospital, Asahi-cho, Maebashi, Gunma, Japan; <sup>8</sup>Division of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan

**BACKGROUND:** The expression of L-type amino-acid transporter 1 (LAT1) is tumour-specific and has been shown to have essential roles in cell growth and survival. However, little is known regarding the clinical significance of LAT1 expression in pancreatic cancer. This study was conducted to determine the prognostic significance of LAT1 expression.

**METHODS:** A total of 97 consecutive patients with surgically resected pathological stage I–IV pancreatic ductal adenocarcinoma were retrospectively reviewed. Tumour sections were stained by immunohistochemistry for LAT1, CD98, Ki-67 and vascular endothelial growth factor (VEGF), and microvessel density was determined by CD34 and p53.

**RESULTS:** L-type amino-acid transporter 1 and CD98 were highly expressed in 52.6% (51/97) and 56.7% (55/97) of cases, respectively ( $P = 0.568$ ). The expression of LAT1 within pancreatic cancer cells was significantly associated with disease stage, tumour size, Ki-67, VEGF, CD34, p53 and CD98. L-type amino-acid transporter 1 expression was confirmed to be a significant prognostic factor for predicting poor outcome by multivariate analysis.

**CONCLUSION:** L-type amino-acid transporter 1 expression is a promising pathological marker for the prediction of outcome in patients with pancreatic cancer.

*British Journal of Cancer* (2012) **107**, 632–638. doi:10.1038/bjc.2012.310 www.bjcancer.com

Published online 17 July 2012

© 2012 Cancer Research UK

**Keywords:** LAT1; CD98; pancreatic cancer; amino-acid transporter; prognostic factor; Ki-67

Pancreatic cancer has a poor prognosis and is the leading cause of cancer death, although the disease represents only 3% of all tumours (Jemal *et al*, 2008). Surgical resection remains the only potentially curative therapeutic option. At the time of initial diagnosis, only a minority of patients with pancreatic cancer are at a disease stage that can still potentially be cured by resection (Geer and Brennan, 1993). Even if a potentially curative resection can be performed, the 5-year overall survival (OS) is low at 10–25% (Geer and Brennan, 1993; Cameron *et al*, 2006). To improve patient outcome, clinical markers that may predict the prognosis and response to the specific therapy should be established. Current prognostic biomarkers for curatively resected pancreatic cancer are thought to be lymph node status, tumour type, histological grade, tumour staging and performance status (Geer and Brennan, 1993; Delcore *et al*, 1996; Cameron *et al*, 2006; Hellan *et al*, 2008). However, no established clinical markers have correlated with outcome and therapeutic response in patients with pancreatic cancer.

Amino-acid transporters are essential for the growth and proliferation of normal cells and transformed cells

(Christensen, 1990; McGivan and Pastor-Anglada, 1994). L-type amino-acid transporter 1 (LAT1) is an L-type amino-acid transporter that transports large neutral amino acids, such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine and histidine (Kanai, *et al*, 1998; Yanagida *et al*, 2001). L-type amino-acid transporter 1 requires covalent association with the heavy chain of 4F2 cell surface antigen (CD98) for its functional expression in the plasma membrane (Kanai *et al*, 1998). L-type amino-acid transporter 1 has been closely associated with cancerous or proliferative cells, and previous studies have shown that LAT1 is highly expressed in proliferating tissues, many tumour cell lines (T24 bladder carcinoma cells, RERF-LC-MA lung small-cell carcinoma cells and HeLa uterine cervical carcinoma cells) and primary human tumours (Yanagida *et al*, 2001; Kobayashi *et al*, 2005; Nawashiro *et al*, 2006; Nakanishi *et al*, 2007; Kaira *et al*, 2008; Sakata *et al*, 2009; Ichinoe *et al*, 2011). Recent studies have demonstrated that the level of LAT1 expression is a significant factor that indicates poor prognosis in various human cancers, including lung cancer (Kaira *et al*, 2008), urologic cancer (Nakanishi *et al*, 2007), brain tumours (Nawashiro *et al*, 2006), prostatic cancer (Sakata *et al*, 2009) and gastric cancer (Ichinoe *et al*, 2011). L-type amino-acid transporter 1 provides cancer cells with the amino acids that are essential not

\*Correspondence: Dr K Kaira; E-mail: kkaira1970@yahoo.co.jp

Received 23 April 2012; revised 14 May 2012; accepted 18 June 2012; published online 17 July 2012

only for protein synthesis but also for the stimulation of cancer cell growth *via* mammalian targeting of rapamycin (Fuchs and Bode, 2006).

Although LAT1 has been described to have a crucial role in the pathogenesis of human neoplasms, the clinical significance of LAT1 expression in pancreatic cancer remains unclear (Fuchs and Bode, 2006; Nawashiro *et al*, 2006; Nakanishi *et al*, 2007; Kaira *et al*, 2008; Sakata *et al*, 2009; Ichinoe *et al*, 2011). Previous studies have demonstrated that LAT1 expression is closely associated with CD98, cell proliferation (Ki-67-labelling index), the cell cycle regulator p53 and angiogenesis in patients with thoracic tumours (Kaira *et al*, 2011a, 2011b). Therefore, in this study, the expression level of LAT1 protein was assessed in resected tissue specimens and correlated with the outcome of patients with pancreatic cancer. In addition, the correlation between LAT1 expression and CD98, the Ki-67-labelling index, p53, and angiogenic markers, such as vascular endothelial growth factor (VEGF) expression and microvessel density (determined by CD34), was examined.

## PATIENTS AND METHODS

### Patients

We analysed 113 consecutive patients with pancreatic ductal adenocarcinoma (AC) who underwent surgical resection at Gunma University Hospital and Maebashi Red Cross Hospital between July 1995 and March 2011. Nine patients who received induction chemotherapy or radiation therapy were excluded. The specimens from seven patients were not available. Thus, a total of 97 patients were analysed in the study. The study protocol was approved by the institutional review board.

The age of the patients ranged from 25 to 86 years, and the median age was 67 years. None of the patients had received neo-adjuvant chemotherapy. All surgical specimens were reviewed and classified according to the WHO classification by an experienced pathologist who was unaware of clinical or imaging findings. Pathological tumour-node-metastasis stages were established using the International System for Staging Pancreatic Cancer adopted by the American Joint Committee on Cancer and the Union Internationale Centre le Cancer (Sobin *et al*, 2009). In all cases, magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography were performed before surgical resection, and intrapancreatic common bile duct carcinoma (cholangiocarcinoma) and ampullary carcinoma were excluded from this study. Histologically, all patients were diagnosed with AC. Of the total patients, 18, 40, 32 and 7 had stage I, II, III and IV tumours, respectively. Postoperative adjuvant chemotherapy with gemcitabine, S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) and oral administration of tegafur (a fluorouracil derivative drug) were administered to 31, 15 and 1 patients, respectively. Intraoperative therapy was not performed on any patient. The day of surgery was considered the starting day for measuring postoperative survival. The follow-up duration ranged from 6 to 164 months (median, 14 months).

A control group of patients with benign pancreatic lesions was also analysed. Immunohistochemical staining of samples from 18 patients with surgically resected benign pancreatic diseases was performed and compared with that of pancreatic cancer. The histology of resected benign pancreatic lesions was as follows: four patients with intraductal papillary-mucinous adenoma, two patients with solid-pseudopapillary tumour, two patients with serous cystadenoma, three patients with pseudocyst, two patients with lymphoplasmacytic sclerosing pancreatitis, two patients with chronic sclerosing pancreatitis, one patient with inflammatory pseudotumour, one patient with pancreatic endocrine cell tumour (insulinoma) and one patient with abscess of pancreas.

### Immunohistochemical staining

L-type amino-acid transporter 1 expression was determined by immunohistochemical staining with a LAT1 antibody (2 mg ml<sup>-1</sup>, anti-human monoclonal mouse antibody, 4A2, provided by Dr H Endou (J-Pharma, Tokyo, Japan), dilution; 1:3200). The production and characterisation of the LAT1 antibody has previously been described (Sakata *et al*, 2009). The CD98 antibody is an affinity-purified rabbit polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 1:100 dilution) raised against a peptide mapping to the carboxy terminus of CD98 of human origin. The detailed protocol for immunostaining has been published elsewhere (Kaira *et al*, 2008). L-type amino-acid transporter 1 and CD98 expression was considered positive only if distinct membrane staining was present. The LAT1 and CD98 expression scores were assessed by the extent of staining as follows: 1, ≤10% of tumour area stained; 2, 11–25% stained; 3, 26–50% stained; and 4, ≥51% stained. The staining intensity was not considered when staining was assessed. The tumours in which stained tumour cells were scored as 3 or 4 were defined as high expression.

For VEGF, CD34, Ki-67 and p53, immunohistochemical staining was performed according to the procedures described in previous reports (Kaira *et al*, 2009, 2010a). The following antibodies were used: a monoclonal antibody against VEGF (Immuno-Biological Laboratories Co. Ltd, Fujioka, Japan, 1:100 dilution); mouse monoclonal antibodies against CD34 (Nichirei, Tokyo, Japan, 1:800 dilution), Ki-67 (Dako, Glostrup, Denmark, 1:40 dilution) and p53 (D07; Dako, 1:50 dilution). The expression of VEGF was quantitatively assessed according to the percentage of immunoreactive cells among a total of 1000 neoplastic cells. The number of CD34-positive vessels was counted in four selected hot spots in a ×400 field (0.26 mm<sup>2</sup> field area). Microvessel density was defined as the mean count of microvessels per 0.26 mm<sup>2</sup> field area. The median rate of VEGF positivity and the median number of CD34-positive vessels were evaluated, and the tumours in which stained tumour cells represented more than each median value were defined as high expression. For p53, microscopic examination for the nuclear reaction product was performed and scored. Based on a previous report (Kaira *et al*, 2010a), p53 expression in greater than 10% of the tumour cells was defined as positive expression. For Ki-67, a highly cellular area of the immunostained sections was evaluated. All epithelial cells with nuclear staining of any intensity were defined as high expression. Approximately 1000 nuclei were counted on each slide. Proliferative activity was assessed as the percentage of Ki-67-stained nuclei (Ki-67-labelling index) in the sample. The median value for the Ki-67-labelling index was evaluated, and the tumour cells with greater than the median value were defined as high expression. The sections were assessed using a light microscope in a blinded fashion by at least two of the authors.

### Statistical analysis

Probability values of <0.05 indicated a statistically significant difference. Fisher's exact test was used to examine the association between two categorical variables. The correlation between different variables was analysed using the nonparametric Spearman's rank test. Follow-up for these 97 patients was conducted using the patient medical records. The Kaplan–Meier method was used to estimate survival as a function of time, and survival differences were analysed by the log-rank test. Overall survival was determined as the time from tumour resection to death from any cause. Progression-free survival (PFS) was defined as the time between tumour resection and the first disease progression or death. Multivariate analyses were performed using a stepwise Cox proportional hazards model to identify independent prognostic factors. Statistical analyses were performed using JMP 8 (SAS Institute Inc., Cary, NC, USA) for Windows.

## RESULTS

### Immunohistochemical analysis


The immunohistochemical analysis of the biomarkers was performed on the 97 primary lesions with pancreatic cancer and 18 resected lesions with benign pancreatic diseases. Figure 1 represents the immunohistochemical staining of LAT1 and CD98 expression in patients with pancreatic cancer. L-type amino-acid transporter 1 immunostaining was detected in carcinoma cells in the tumour tissues and was localised predominantly on the plasma membrane. All positive cells revealed strong membranous LAT1 immunostaining. Cytoplasmic staining was rarely observed. In the 97 patients with pancreatic cancer, high LAT1 and CD98 expression was recognised in 52.6% (51/97) and 56.7% (55/97) of cases, respectively ( $P=0.568$ ). Among the 18 patients with benign pancreatic diseases, high LAT1 and CD98 expression was observed in 0% (0/18) and 44.4% (8/18) of cases, respectively ( $P=0.003$ ). The rate of high LAT1 and CD98 expression was significantly higher in pancreatic cancer than in benign pancreatic diseases (LAT1,  $P<0.001$ ; CD98,  $P=0.026$ ). The average LAT1 and CD98 expression scores in pancreatic cancer were  $2.4 \pm 0.9$  and  $2.6 \pm 0.8$  on a scale of 1–4, respectively ( $P=0.232$ ); these scores in benign pancreatic diseases were  $1.6 \pm 0.5$  and  $2.4 \pm 1.0$ , respectively ( $P=0.002$ ). The LAT1 expression scores were significantly higher in pancreatic cancer than in benign diseases ( $P<0.001$ ), but the CD98 expression scores were not significantly different between

malignant and benign lesions ( $P=0.528$ ) (Supplementary Figure A1, online only). Among the 51 patients with high LAT1 expression (score of 3 or 4), 39 (76.5%) displayed high expression of CD98 (score of 3 or 4) and 12 displayed low expression (6 patients with a score of 2 and 6 patients with a score of 1) (Figure 1A). In these six patients with a score of 1, no evidence of CD98 immunostaining was present.

The median rate of VEGF positivity was 40% (range, 5–80), and the value of 40% was chosen as a cutoff point. The median number of CD34 was 26 (range, 3–60), and the value of 26 was chosen as a cutoff point. The median value for the Ki-67-labelling index was 27% (range, 3–68), and the value of 27% was chosen as a cutoff point. Positive p53 expression was recognised in 40.2% (39/97) of cases. Table 1 shows the comparison of these biomarkers between pancreatic cancers and benign lesions. The rate of high expression or positivity of these biomarkers was significantly higher in pancreatic cancers than in benign pancreatic lesions.

### Demographics of patients according to LAT1 expression

The demographic distribution of the other variables according to LAT1 expression is listed in Table 2. A statistically significant difference in disease stage, T factor, lymphatic permeation, vascular invasion and expression of CD98, Ki-67, VEGF, CD34 and p53 was observed between samples with high LAT1 and low LAT1 expression.



**Figure 1** Immunohistochemical staining of tissue from a 60-year-old man with pancreatic ductal AC (p-stage IB). L-type amino-acid transporter 1 (**A**) immunostaining (score 4) displays a membranous immunostaining pattern but no evidence of CD98 (**B**) immunostaining (score 1). Immunostaining of LAT1 (**C**) and CD98 (**D**) in tissue from a 67-year-old man with pancreatic ductal AC (p-stage IIIB) showed a membranous immunostaining pattern in nearly the same area. The LAT1 and CD98 scores were 3 and 3, respectively. (**E**) shows negative staining for LAT1 in a patient with pancreatic ductal AC.



## Correlation between LAT1 expression and different variables

Using Spearman's rank correlation, a significant correlation was observed between LAT1 and CD98, Ki-67, VEGF, CD34 and tumour size (Table 3). Among the 18 patients with benign pancreatic diseases, the expression of LAT1 significantly correlated with CD98 expression ( $\gamma=0.541$ ,  $P=0.020$ ) but not with VEGF ( $\gamma=0.261$ ,  $P=0.296$ ), Ki-67 ( $\gamma=0.175$ ,  $P=0.488$ ) or CD34 ( $\gamma=0.293$ ,  $P=0.238$ ).

## Different variables and survival analysis

The 5-year and 2-year survival rates and median survival time for all patients were 30.8%, 40.8% and 18.0 months (95% confidence interval 12.9–24.6), respectively. Among all of the patients, 65 experienced postoperative recurrence, 26 received systemic chemotherapy with gemcitabine or S-1, and 53 died owing to disease progression. Tables 4 and 5 show the univariate and multivariate analysis of all patients ( $n=97$ ). In the univariate analysis, disease stage, lymphatic permeation, vascular invasion

and the expression of LAT1, Ki-67 and VEGF were significantly associated with poor PFS and OS. CD98 expression yielded a statistically significant difference in OS. Figure 2 shows the Kaplan–Meier survival curve in patients with high and low LAT1 and CD98 expression. Based on the results of the univariate log-rank test, we screened prognostic factors with a cutoff of  $P<0.05$ . Multivariate analysis confirmed that LAT1, Ki-67 and disease stage were independent prognostic factors for predicting poor OS. However, no significant independent prognostic factor was observed in the multivariate analysis of PFS.

Next, we performed survival analysis based on the LAT1 expression status. Multivariate analysis confirmed that disease stage and Ki-67 were independent prognostic factors for predicting poor PFS and OS in 51 patients with high LAT1 expression (Supplementary Table A1, online only). However, in 46 patients with low LAT1 expression, Ki-67 was confirmed to be a significant prognostic factor for predicting poor PFS by multivariate analysis (Supplementary Table A2, online only).

## DISCUSSION

This study is the first to evaluate the clinical significance of LAT1 expression in pancreatic cancer and clearly demonstrated that the expression of LAT1 was a significant independent factor for

**Table 1** Comparison of different variables between pancreatic cancers and benign lesions

Variables	Rate of high expression or positivity (%) in various biomarkers		P-value
	Pancreatic cancers (n = 97)	Pancreatic benign lesions (n = 18)	
Age ( $\leq 65 / > 65$ )	(43/54)	(10/8)	0.445
Gender (male/female)	(48/49)	(7/11)	0.451
LAT1 (high/low)	52.6% (51/97)	0% (0/18)	<b>&lt; 0.001</b>
CD98 (high/low)	56.7% (55/97)	44.4% (8/18)	<b>0.026</b>
Ki-67 (high/low)	49.5% (48/97)	5.5% (1/18)	<b>&lt; 0.001</b>
VEGF (high/low)	44.3% (43/97)	16.7% (3/18)	<b>0.035</b>
CD34 (high/low)	49.5% (48/97)	22.2% (4/18)	<b>0.040</b>
p53 (positive/negative)	40.2% (39/97)	0% (0/18)	<b>&lt; 0.001</b>

Abbreviations: LAT1 = L-type amino-acid transporter 1; VEGF = vascular endothelial growth factor. Bold values indicate a statistically significant difference.

**Table 3** Correlation between LAT1 and other biomarkers in pancreatic cancer

Biomarkers	Spearman $\gamma$ (95% CI)	P-value
CD98	0.433 (0.251–0.586)	<b>&lt; 0.001</b>
Ki-67	0.498 (0.326–0.638)	<b>&lt; 0.001</b>
VEGF	0.538 (0.374–0.669)	<b>&lt; 0.001</b>
CD34	0.357 (0.162–0.524)	<b>&lt; 0.001</b>
Tumour size	0.248 (0.045–0.431)	<b>0.014</b>
CEA	0.020 (–0.185 to 0.224)	0.845
CA19-9	–0.038 (–0.241 to 0.168)	0.708

Abbreviations: LAT1 = L-type amino-acid transporter 1; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen 19-9; VEGF = vascular endothelial growth factor; 95 CI = 95% confidence interval. Bold values indicate a statistically significant difference.

**Table 2** Patient's demographics according to LAT1 expression

Variables		Total (n = 97) (%)	LAT1 expression		P-value
			High (n = 51) (%)	Low (n = 46) (%)	
Age (years)	$\leq 65 / > 65$	43/54 (44/56)	21/30 (41/59)	22/24 (48/52)	0.544
Gender	Male/female	48/49 (49/51)	23/28 (45/55)	25/21 (54/46)	0.418
Disease stage	I–II/III–IV	58/39 (60/40)	25/26 (49/51)	33/13 (72/28)	<b>0.037</b>
T factor	T1–2/T3–4	24/73 (25/75)	6/45 (12/88)	15/31 (33/67)	<b>0.015</b>
N factor	N0/N1–2	40/57 (41/59)	17/34 (33/67)	23/23 (50/50)	0.104
M factor	M0/M1	90/7 (93/7)	45/6 (88/12)	45/1 (98/2)	0.114
Lymphatic permeation	Positive/negative	81/16 (84/16)	47/4 (92/8)	34/12 (74/26)	<b>0.026</b>
Vascular invasion	Positive/negative	67/30 (69/31)	45/6 (88/12)	22/24 (48/52)	<b>&lt; 0.001</b>
Differentiation	WD—MD/PD	84/13 (87/13)	41/10 (80/20)	43/3 (93/7)	0.076
Tumour site	Head/body–tail	66/31 (68/32)	35/16 (67/33)	31/15 (67/33)	$> 0.999$
CEA ( $\text{ng ml}^{-1}$ )	$\leq 30 / > 30$	51/46 (53/47)	27/24 (53/47)	24/22 (52/48)	$> 0.999$
Adjuvant chemotherapy	Yes/no	52/45 (54/46)	32/19 (63/37)	20/26 (43/57)	0.068
CD98	High/low	55/42 (57/43)	39/12 (76/24)	16/30 (35/65)	<b>&lt; 0.001</b>
Ki-67	High/low	48/49 (49/51)	32/19 (63/37)	16/30 (35/65)	<b>&lt; 0.001</b>
VEGF	High/low	42/55 (43/57)	34/17 (67/33)	8/38 (17/83)	<b>&lt; 0.001</b>
CD34	High/low	48/49 (49/51)	37/14 (73/27)	11/35 (24/76)	<b>&lt; 0.001</b>
p53	Positive/negative	36/61 (37/63)	25/26 (49/51)	11/35 (24/76)	<b>&lt; 0.001</b>

Abbreviations: LAT1 = L-type amino-acid transporter 1; CEA = carcinoembryonic antigen; VEGF = vascular endothelial growth factor; WD = well differentiated; MD = moderately differentiated; PD = poorly differentiated. Bold values indicate a statistically significant difference.

**Table 4** Univariate and multivariate analysis in progression-free survival

Variables		Univariate analysis		Multivariate analysis		
		5-year rate (%)	P-value	Hazard ratio	95% CI	P-value
Age (years)	≤65/>65	27.9/23.4	0.910			
Gender	M/F	34.0/14.5	0.068			
Disease stage	I–II/III–IV	35.3/15.4	<b>0.003</b>	1.223	0.946–1.607	0.122
CEA (ng ml <sup>-1</sup> )	≤30/>30	29.9/20.5	0.121			
CA19-9 (U ml <sup>-1</sup> )	≤132/>132	36.3/18.1	0.110			
Residual margin	R0/R1 or R2	30.7/10.5	0.051			
Lymphatic permeation	P/N	21.7/53.8	<b>0.010</b>	1.548	0.638–4.357	0.348
Vascular invasion	P/N	15.0/49.6	< <b>0.001</b>	1.397	0.789–2.386	0.243
Adjuvant chemotherapy	Yes/no	25.4/27.4	0.878			
LAT1	High/low	0.0/45.3	< <b>0.001</b>	1.226	0.873–1.734	0.241
CD98	High/low	17.8/37.1	0.071			
Ki-67	High/low	0.0/41.0	< <b>0.001</b>	1.835	0.936–3.792	0.077
VEGF	High/low	8.5/38.2	< <b>0.001</b>	1.132	0.842–1.541	0.415
CD34	High/low	17.6/34.0	0.582			
p53	High/low	22.8/28.4	0.515			

Abbreviations: M/F = male/female; LAT1 = L-type amino-acid transporter 1; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen 19-9; VEGF = vascular endothelial growth factor; P/N = positive/negative; CI = confidence interval. Bold values indicate a statistically significant difference.

**Table 5** Univariate and multivariate analysis in overall survival


Variables		Univariate analysis		Multivariate analysis		
		5-year rate (%)	P-value	Hazard ratio	95% CI	P-value
Age (years)	≤65/>65	33.0/33.1	0.908			
Gender	M/F	39.6/24.8	0.225			
Disease stage	I–II/III–IV	43.4/17.3	<b>0.002</b>	2.209	1.025–5.114	<b>0.047</b>
CEA (ng ml <sup>-1</sup> )	≤30/>30	38.6/23.8	0.211			
CA19-9 (U ml <sup>-1</sup> )	≤132/>132	44.6/25.7	0.216			
Residual margin	R0/R1 or R2	34.6/19.7	0.093			
Lymphatic permeation	P/N	23.5/69.3	<b>0.009</b>	0.311	0.025–2.286	0.268
Vascular invasion	P/N	15.2/65.5	< <b>0.001</b>	0.915	0.686–1.212	0.538
Adjuvant chemotherapy	Yes/no	32.1/27.7	0.423			
LAT1	High/low	0.0/60.7	< <b>0.001</b>	1.590	1.085–2.368	<b>0.017</b>
CD98	High/low	24.6/43.8	<b>0.048</b>	0.856	0.607–1.213	0.380
Ki-67	High/low	0.0/51.9	< <b>0.001</b>	1.617	1.215–2.179	< <b>0.001</b>
VEGF	High/low	8.3/48.7	<b>0.003</b>	0.872	0.627–1.204	0.411
CD34	High/low	21.5/45.2	0.095			
p53	High/low	21.0/40.3	0.119			

Abbreviations: M/F = male/female; LAT1 = L-type amino-acid transporter 1; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen 19-9; VEGF = vascular endothelial growth factor; P/N = positive/negative; CI = confidence interval. Bold values indicate a statistically significant difference.

predicting poor outcome in patients with surgically resected pancreatic cancer. Moreover, our study showed that LAT1 expression was significantly associated with disease stage, tumour size, tumour proliferation (Ki-67), angiogenesis (VEGF and CD34), the cell cycle regulator p53 and CD98 expression. CD98 has a crucial role in the functional expression of LAT1; therefore, LAT1 directly correlated with the expression of CD98. A recent study has documented that CD98 expression within tumour cells significantly correlates with angiogenesis (VEGF and CD34) and p53 (Kaira et al. 2010b). As LAT1 expression is significantly associated with cell proliferation (Ki-67) in various neoplasms (Kaira et al, 2008; Furuya et al. 2012), we hypothesised that LAT1 expression within pancreatic tumour cells also directly correlated with these molecular markers.

The expression of LAT1 is tumour-specific and has been shown to have essential roles in cell growth and survival. Recent studies have shown that high LAT1 expression is significantly associated with cell proliferation, angiogenesis and poor outcome in patients with various human neoplasms (Kobayashi et al, 2005; Nawashiro et al, 2006; Nakanishi et al, 2007; Kaira et al, 2008; Sakata et al, 2009; Ichinoe et al, 2011). However, little is known regarding the clinical significance of LAT1 expression in various human cancers,

such as pancreatic cancer, colorectal cancer, skin tumours (melanoma), sarcoma, head and neck cancer, hepatic cancer and malignant lymphoma. In the present study, LAT1 was highly expressed in pancreatic cancer cells compared with non-malignant pancreatic cells, and the high expression of LAT1 protein within pancreatic cancer cells closely correlated with dismal postoperative survival regardless of adjuvant chemotherapy. One *in vitro* study has also documented that LAT1 expression in Colo357 cells (human ductal pancreatic AC cells) is higher than that in non-malignant controls (von Forstner et al, 2011). Interestingly, LAT1 closely correlated with the expression of CD98 in pancreatic malignant and benign cells, but the expression of LAT1 within non-malignant cells did not significantly correlate with angiogenesis, cell proliferation or cell cycle regulation. Our results indicate that CD98 is essential for the functional expression of LAT1 in malignant and non-malignant cells. However, CD98 expression was absent in 6 (11.7%) of 51 patients with high LAT1 expression. Our results suggest that not all patients with pancreatic AC have cooperative expression of LAT1 with CD98, but the reason for the discrepancy in their expression remains unknown. The expression of CD98 has been documented to be elevated in a variety of carcinomas and to have a crucial role in tumour progression



**Figure 2** Kaplan–Meier analysis of OS according to LAT1 (A) and CD98 expression (B). A statistically significant difference in OS was observed between the patients with high LAT1 and those with low LAT1 tumour expression ( $P < 0.0001$ ), and between the patients with high and low CD98 tumour expression ( $P = 0.0486$ ).

and metastasis of human neoplasms; CD98 expression could also represent a significant prognostic factor for predicting poor outcome in lung cancer (Kaira *et al*, 2009). However, our study did not identify CD98 expression as a significant independent prognostic marker in pancreatic cancer. As CD98 is frequently expressed in benign pancreatic diseases, CD98 may not be a tumour-specific marker in pancreatic tumours.

A recent review has summarised the immunohistochemical biomarkers with prognostic significance in patients with pancreatic cancer and concluded that none of the molecular markers can be recommended for routine clinical use (Ansari *et al*, 2011). However, several small studies have identified the Ki-67 index as an independent predictor of survival in pancreatic cancer (Linder *et al*, 1997; Shyr *et al*, 1999; Yamamoto *et al*, 2004; Karamitopoulou *et al*, 2010). Among the prognostic factors Ki-67, p21, p27 and p53, only the Ki-67 index has been described to show

prognostic significance in 77 patients with pancreatic ductal AC by multivariate analysis (Yamamoto *et al*, 2004). Moreover, two immunohistochemical studies have demonstrated a significant correlation between p53-positive tumours and poor outcome (Linder *et al*, 1997; Ahrendt *et al*, 2000), 3 of 18 studies have identified VEGF as an independent prognostic marker (Ikeda *et al*, 1999; Sun *et al*, 2007; Ai *et al*, 2008), and only CD34 has been described to be associated with outcome by multivariate analysis in two studies (Ikeda *et al*, 1999; Fujioka *et al*, 2001). However, other studies have found no relationship between these molecular markers and survival in pancreatic cancer (Ansari *et al*, 2011). Therefore, whether the presence of these molecular markers has any prognostic implications remains unclear. The results of our study identified the Ki-67 index as an independent prognostic factor for predicting poor outcome. The level of cell proliferation may have a significant prognostic implication in tumour cells with high LAT1 expression. Although a recent retrospective study has demonstrated that patients with adjuvant therapy have more adverse prognostic factors than those without adjuvant therapy (Corsini and Miller, 2008), LAT1 and the Ki-67 index were associated with prognostic significance regardless of adjuvant therapy. However, the prognostic role of Ki-67 varies between different studies. The expression profile of Ki-67 differs between the studies, and the methods used in the studies also vary. Therefore, optimisation and standardisation of these molecular techniques is necessary. Further study is warranted to confirm our results using a large number of patients with pancreatic cancer.

The limitations of this study must be addressed. Our study analysed the outcome of subgroups based on high and low LAT1 expression. As this study analysed the survival of small groups, the subgroup analysis may bias our results. Further study is warranted to analyse a large number of patients with pancreatic cancer and to investigate the optimal cutoff points for the expression level of LAT1.

In conclusion, high expression of LAT1 (measured by immunostaining) can serve as an independent prognostic marker to predict poor outcome after surgical resection and may be an important clinical marker of therapy for pancreatic AC. Inhibition of LAT1 function may arrest tumour growth, and LAT1 represents an attractive target for adjuvant therapy in the future.

## ACKNOWLEDGEMENTS

This work was supported in part by Grant 23591750 (KK) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the National Hospital Organisation Policy Based Medical Services. We thank Ms Masako Saito for technical assistance with the immunohistochemical analysis.

## Conflict of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

## REFERENCES

- Ahrendt SA, Brown HM, Komorowski RA, Zhu YR, Wilson SD, Erickson BA, Erickson BA, Ritch PS, Pitt HA, Demeure MJ (2000) p21 WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. *Surgery* **128**: 520–530
- Ai KX, Lu LY, Huang XY, Chen W, Zhang HZ (2008) Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. *World J Gastroenterol* **14**: 1931–1935

- Ansari D, Rosendahl A, Elebro J, Andersson R (2011) Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. *Br J Surg* **98**: 1041–1055
- Cameron JL, Riall TS, Coleman J, Belcher KA (2006) One thousand consecutive pancreaticoduodenectomies. *Ann Surg* **244**: 10–15
- Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnel MB, Nagorney DM, Jatoti A, McWilliams RR, Kim GP, Bhatia S, Iott MJ,

- Gunderson LL (2008) Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic Experience (1975-2005). *J Clin Oncol* 26: 3511-3516
- Christensen HN (1990) Role of amino acid transport and countertransport in nutrition and metabolism. *Physiol Rev* 70: 43-77
- Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH (1996) Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. *Am J Surg* 172: 463-468
- Fuchs BC, Bode BP (2006) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? *Semin Cancer Biol* 15: 254-266
- Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y (2001) Angiogenesis in pancreatic carcinomas: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. *Cancer* 92: 1788-1797
- Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T (2012) Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. *Cancer Sci* 103: 382-389
- Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. *Am J Surg* 165: 68-72
- Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn JD, Kim J (2008) The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. *Pancreas* 37: 19-24
- Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H, Okayasu I (2011) High expression of L-type amino acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. *Pathol Int* 61: 281-289
- Ikedo N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M (1999) Prognostic significance of angiogenesis in human pancreatic cancer. *Br J Cancer* 79: 1553-1563
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. *CA Cancer J Clin* 58: 71
- Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. *Br J Cancer* 98: 742-748
- Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M (2009) CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. *Ann Surg Oncol* 16: 3473-3481
- Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, Koh Y, Hanaoka H, Tominaga H, Oriuchi N, Kondo H, Nakajima T, Yamamoto N (2010a) Biologic correlation of 2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. *J Clin Oncol* 28: 3746-3753
- Kaira K, Takahashi T, Abe M, Akamatsu H, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Kondo H, Nakajima T, Endo M, Yamamoto N (2010b) CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. *Oncol Rep* 24: 861-867
- Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N (2011a) LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. *Am J Transl Res* 3: 468-478
- Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N (2011b) L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. *Anticancer Res* 31: 4075-4082
- Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Neutron cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). *J Biol Chem* 273: 23629-23632
- Karamitopoulou E, Zlobec I, Tornillo L, Carafa V, Schaffner T, Brunner T, Borner M, Diamantis I, Zimmermann A, Terracciano L (2010) Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (Pan IN). *Pathology* 42: 229-234
- Kobayashi H, Ishii Y, Takayama T (2005) Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. *J Surg Oncol* 90: 233-238
- Linder S, Parrado C, Falkmer UG, Blasjo M, Sundelin P, von Rosen A (1997) Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumour material. *Br J Cancer* 76: 54-59
- McGivan JD, Pastor-Anglada M (1994) Regulatory and molecular aspects of mammalian amino acid transport. *Biochem J* 299: 321-334
- Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Kawai T (2007) Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. *Virchows Arch* 451: 681-690
- Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. *Int J Cancer* 119: 484-492
- Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H, Okayasu I (2009) L-type amino acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. *Pathol Int* 59: 7-18
- Shyr YM, Su CH, Li AF, Wu CW, Lui WY (1999) The role of MIB-1 index in the prognosis of resectable pancreatic head cancer. *Hepatogastroenterology* 46: 2968-2973
- Sobin LH, Gospodarowicz MK, Ch Wittekind (2009) (eds) *International Union Against Cancer (UICC) TNM Classification of Malignant Tumors*. 7th edn. Wiley-Blackwell: Oxford, UK
- Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ, Yao M, Huang C (2007) Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. *Int J Oncol* 30: 1359-1367
- von Forstner C, Zuhayra M, Ammerpohl O, Zhao Y, Tiwari S, Jansen O, Kalthoff H, Henze E, Egberts JH (2011) Expression of L amino acid transporter system 1 and analysis of iodine-123-methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused high-resolution-micro-SPECT-MRI. *Hepatobiliary Pancreat Dis Int* 10: 30-37
- Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K (2004) Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. *Clin Cancer Res* 10: 2846-2850
- Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H (2001) Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. *Biochim Biophys Acta* 1514: 291-302

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.